National Biodefense Analysis and Countermeasures Center, Frederick, Maryland, USA.
Department of Immunology, UConn Health, Farmington, Connecticut, USA.
Cytometry A. 2020 Jul;97(7):674-680. doi: 10.1002/cyto.a.24040. Epub 2020 Jun 3.
In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. © 2020 International Society for Advancement of Cytometry.
针对最近的 COVID-19 大流行,许多实验室都参与了支持 SARS-CoV-2 疫苗开发和临床试验的研究。流式细胞术实验室将通过分选未经固定的抗原特异性淋巴细胞,在这项工作中承担很大一部分责任。因此,我们及时了解传染性细胞分选的风险评估和既定程序至关重要。在此,我们介绍了涵盖分选未经固定的 SARS-CoV-2 感染细胞和其他类似风险级别的传染性病原体的生物安全方面的程序。这些程序遵循国际细胞分析学会生物安全委员会的指南,最近已获得美国国立卫生研究院机构生物安全委员会的批准,可用于分选 SARS-CoV-2 感染细胞。© 2020 国际细胞分析学会。